-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the development of the pharmaceutical industry, R&D investment is very important.
It not only indicates the company's innovation ability, but also determines the future development direction of an enterprise
.
It is understood that with the continuous increase of the state's support for the development of innovative drugs, many companies have also increased their investment in research and development
.
According to statistics, in 2021, in the A-share + H-share pharmaceutical and biological industry (Shenwan industry classification), a total of 59 listed companies have an operating income of over 10 billion yuan, of which 51 have announced their R&D investment, with a total amount of 40.
819 billion yuan, an increase of 18% year-on-year, or an increase of 6.
222 billion yuan; it is worth mentioning that 37 companies invested more than 100 million yuan in research and development, accounting for more than 70%
.
Among them, four listed companies including Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, and CSPC have invested more than 3 billion yuan in research and development
.
For example, Hengrui Medicine disclosed in its annual report that in 2021, Hengrui Medicine will continue to increase investment in research and development in the face of severe and complex competitive environment and industrial changes.
The proportion of sales revenue reached 23.
95%, a record high for the company
.
Fosun Pharma has also continued to increase R&D investment.
In 2021, R&D investment will total 4.
975 billion yuan, a year-on-year increase of 24.
28%; of which, research and development expenses will be 3.
834 billion yuan, an increase of 1.
039 billion yuan or 37.
17% year-on-year
.
In terms of innovative research and development, Fosun Pharma continued to increase investment in research and development
.
In 2021, the R&D investment will total 4.
975 billion yuan, a year-on-year increase of 24.
28%; of which, the research and development expenses will be 3.
834 billion yuan, an increase of 1.
039 billion yuan and a year-on-year increase of 37.
17%
.
The pharmaceutical business R&D investment was 4.
486 billion yuan, an increase of 22.
23% year-on-year, and the pharmaceutical business R&D investment accounted for 15.
52% of the pharmaceutical business revenue; among which, the R&D expenses were 3.
359 billion yuan, an increase of 891 million yuan or 36.
10% year-on-year, accounting for 3.
359 billion yuan of the pharmaceutical business revenue.
11.
62%
.
China Biopharma's total R&D investment in 2021 will reach 3.
82 billion yuan, a year-on-year increase of 34.
5% (accounting for 14.
2% of revenue)
.
Among them, the research and development investment of innovative drugs and biological drugs accounted for more than 70%, and the investment amount increased by 64.
7% year-on-year.
The research and development investment in the anti-tumor field reached 75%, and the investment amount increased by 71.
2% year-on-year
.
CSPC will also continue to increase investment in research and development in 2021
.
Data show that in 2021, CSPC's research and development expenses will be about 3.
433 billion yuan, an increase of 18.
8% year-on-year, accounting for about 15.
1% of the revenue of the patented drug business
.
In addition, according to statistics, the R&D investment of 47 companies increased year-on-year, accounting for 92% of the increase
.
At the same time, among the 59 companies mentioned above, 44 pharmaceutical companies announced the number of R&D personnel, of which 35 have an increasing number of R&D personnel, accounting for nearly 80% of the sample
.
For example, WuXi AppTec's R&D personnel increased by 6,899, a year-on-year increase of 31%
.
Analysts said that under the external environment of industry reform and intensified competition, the adjustment of China's pharmaceutical industry has entered a deep-water period
.
2021 is the first year of the "14th Five-Year Plan" strategic plan.
Throughout the year, "ups and downs, overall upward" is the main theme of the development of the pharmaceutical industry.
Compared with the global pharmaceutical market, China's pharmaceutical market still has a large development space
.
In the face of the severe and complex competitive environment and industrial changes, increasing R&D investment has become the focus of many pharmaceutical companies in 2021
.
From a long-term perspective, innovative drug companies with blockbuster products focus more on product competitiveness and follow-up commercialization capabilities
.
However, industry insiders pointed out that the industry is still in the adjustment period and labor pain period of transformation and upgrading, and the homogeneous competition will continue for a long time in the future
.
With the improvement of the threshold for innovation and R&D, industry pharmaceutical and biological enterprises with truly innovative capabilities and differentiated R&D pipelines may usher in a broader space for development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
It not only indicates the company's innovation ability, but also determines the future development direction of an enterprise
.
It is understood that with the continuous increase of the state's support for the development of innovative drugs, many companies have also increased their investment in research and development
.
According to statistics, in 2021, in the A-share + H-share pharmaceutical and biological industry (Shenwan industry classification), a total of 59 listed companies have an operating income of over 10 billion yuan, of which 51 have announced their R&D investment, with a total amount of 40.
819 billion yuan, an increase of 18% year-on-year, or an increase of 6.
222 billion yuan; it is worth mentioning that 37 companies invested more than 100 million yuan in research and development, accounting for more than 70%
.
Among them, four listed companies including Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, and CSPC have invested more than 3 billion yuan in research and development
.
For example, Hengrui Medicine disclosed in its annual report that in 2021, Hengrui Medicine will continue to increase investment in research and development in the face of severe and complex competitive environment and industrial changes.
The proportion of sales revenue reached 23.
95%, a record high for the company
.
Fosun Pharma has also continued to increase R&D investment.
In 2021, R&D investment will total 4.
975 billion yuan, a year-on-year increase of 24.
28%; of which, research and development expenses will be 3.
834 billion yuan, an increase of 1.
039 billion yuan or 37.
17% year-on-year
.
In terms of innovative research and development, Fosun Pharma continued to increase investment in research and development
.
In 2021, the R&D investment will total 4.
975 billion yuan, a year-on-year increase of 24.
28%; of which, the research and development expenses will be 3.
834 billion yuan, an increase of 1.
039 billion yuan and a year-on-year increase of 37.
17%
.
The pharmaceutical business R&D investment was 4.
486 billion yuan, an increase of 22.
23% year-on-year, and the pharmaceutical business R&D investment accounted for 15.
52% of the pharmaceutical business revenue; among which, the R&D expenses were 3.
359 billion yuan, an increase of 891 million yuan or 36.
10% year-on-year, accounting for 3.
359 billion yuan of the pharmaceutical business revenue.
11.
62%
.
China Biopharma's total R&D investment in 2021 will reach 3.
82 billion yuan, a year-on-year increase of 34.
5% (accounting for 14.
2% of revenue)
.
Among them, the research and development investment of innovative drugs and biological drugs accounted for more than 70%, and the investment amount increased by 64.
7% year-on-year.
The research and development investment in the anti-tumor field reached 75%, and the investment amount increased by 71.
2% year-on-year
.
CSPC will also continue to increase investment in research and development in 2021
.
Data show that in 2021, CSPC's research and development expenses will be about 3.
433 billion yuan, an increase of 18.
8% year-on-year, accounting for about 15.
1% of the revenue of the patented drug business
.
In addition, according to statistics, the R&D investment of 47 companies increased year-on-year, accounting for 92% of the increase
.
At the same time, among the 59 companies mentioned above, 44 pharmaceutical companies announced the number of R&D personnel, of which 35 have an increasing number of R&D personnel, accounting for nearly 80% of the sample
.
For example, WuXi AppTec's R&D personnel increased by 6,899, a year-on-year increase of 31%
.
Analysts said that under the external environment of industry reform and intensified competition, the adjustment of China's pharmaceutical industry has entered a deep-water period
.
2021 is the first year of the "14th Five-Year Plan" strategic plan.
Throughout the year, "ups and downs, overall upward" is the main theme of the development of the pharmaceutical industry.
Compared with the global pharmaceutical market, China's pharmaceutical market still has a large development space
.
In the face of the severe and complex competitive environment and industrial changes, increasing R&D investment has become the focus of many pharmaceutical companies in 2021
.
From a long-term perspective, innovative drug companies with blockbuster products focus more on product competitiveness and follow-up commercialization capabilities
.
However, industry insiders pointed out that the industry is still in the adjustment period and labor pain period of transformation and upgrading, and the homogeneous competition will continue for a long time in the future
.
With the improvement of the threshold for innovation and R&D, industry pharmaceutical and biological enterprises with truly innovative capabilities and differentiated R&D pipelines may usher in a broader space for development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
